Acadia Pharmaceuticals
ACAD · Pharmaceuticals
$19.73
2.9%Collegium Pharmaceutical
COLL · Pharmaceuticals
$22.96
2.3%The short version
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $781M for Collegium Pharmaceutical.
- Collegium Pharmaceutical grew revenue faster (23.6%, against 11.9%).
- Collegium Pharmaceutical kept more of each dollar of sales as operating profit (23.0% operating margin, against 9.8% operating margin).
- Collegium Pharmaceutical turned more of its sales into free cash flow (42.0% FCF margin, against 9.8% FCF margin).
- Investors pay more for each dollar of Collegium Pharmaceutical’s earnings: a P/E of 18.5x against 8.8x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD · FY25 | COLL · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $746M |
| Revenue | $1.1B | $781M |
| Free cash flow | $105M | $328M |
| Net income | $391M | $62.9M |
| Growth | ||
| Revenue growth | 11.9% | 23.6% |
| 5-year growth | 19.4% | 20.3% |
| Share count change | 2.1% | −1.8% |
| Profitability | ||
| Gross margin | 91.7% | 59.4% |
| Operating margin | 9.8% | 23.0% |
| Net margin | 36.5% | 8.1% |
| FCF margin | 9.8% | 42.0% |
| Return on capital | — | 53.4% |
| Return on equity | 39.9% | 23.7% |
| Balance sheet | ||
| Net debt | — | −$149M |
| Net debt / EBITDA | — | −0.4x |
| Dividends and buybacks | $0.0M | $25.1M |
| Valuation & quality | ||
| P/E | 8.8x | 18.5x |
| Piotroski F-score | — | 6 |
FY16
ACAD $17.3M
COLL $1.7M
FY17
ACAD $125M
COLL $28.5M
FY18
ACAD $224M
COLL $280M
FY19
ACAD $339M
COLL $297M
FY20
ACAD $442M
COLL $310M
FY21
ACAD $484M
COLL $277M
FY22
ACAD $517M
COLL $464M
FY23
ACAD $726M
COLL $567M
FY24
ACAD $958M
COLL $631M
FY25
ACAD $1.1B
COLL $781M
ACAD
COLL
FY16
ACAD −1,574.1%
COLL −5,498.7%
FY17
ACAD −234.1%
COLL −265.0%
FY18
ACAD −110.6%
COLL −7.4%
FY19
ACAD −72.7%
COLL −8.0%
FY20
ACAD −64.9%
COLL 18.1%
FY21
ACAD −35.2%
COLL 6.4%
FY22
ACAD −43.2%
COLL 7.2%
FY23
ACAD −10.1%
COLL 29.5%
FY24
ACAD 24.1%
COLL 26.9%
FY25
ACAD 9.8%
COLL 23.0%
ACAD
COLL
FY16
ACAD −$210M
COLL −$75.5M
FY17
ACAD −$219M
COLL −$68.0M
FY18
ACAD −$170M
COLL $164M
FY19
ACAD −$152M
COLL $21.3M
FY20
ACAD −$144M
COLL $88.4M
FY21
ACAD −$127M
COLL $102M
FY22
ACAD −$114M
COLL $123M
FY23
ACAD $16.7M
COLL $274M
FY24
ACAD $157M
COLL $203M
FY25
ACAD $105M
COLL $328M
ACAD
COLL
FY16
ACAD —
COLL —
FY17
ACAD —
COLL —
FY18
ACAD —
COLL —
FY19
ACAD —
COLL —
FY20
ACAD —
COLL —
FY21
ACAD —
COLL 10.4%
FY22
ACAD —
COLL 16.5%
FY23
ACAD —
COLL 68.7%
FY24
ACAD —
COLL 53.0%
FY25
ACAD —
COLL 53.4%
ACAD
COLL
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.